Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 11 - 20 of 57

Selected Filters:
4 March 2024

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women

This article from the Journal of the American Medical Association describes the results of a pooled analysis to measure HIV incidence among cisgender women with different adherence trajectories to oral PrEP with TDF/FTC.

Research

External Link
4 March 2024

Coordinating Implementation Science for CAB for PrEP: Early Insights from EBONI and PILLAR

This document summarises key takeaways from the BioPIC Think Tank on early insights from ViiV Healthcare’s two cabotegravir for PrEP implementation studies- EBONI and PILLAR.

Research, Service Delivery

Document
22 February 2024

Impact of PrEP Expansion in the USA

This memorandum from RTI International applies updated estimates of current HIV incidence in the United States to the PrEP Cost Calculator to estimate the impact of PrEP expansion.

Financing & Costing

Document
14 November 2023

Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…

Research

External Link
11 October 2023

HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South

Recording / Slides / Resources Please join The Choice Agenda and partners on November 15 for a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Visit the study website here. Speakers will…

Research

Event
9 October 2023

Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial

This article from the Lancet HIV discusses the results of a secondary analysis of data from the HPTN 083 trial of cabotegravir for PrEP, looking specifically at the cohort of transgender women included in the study.

Research

External Link
6 October 2023

Integrating HIV Preexposure Prophylaxis With Community-Based Syringe Services for Women Who Inject Drugs: Results from the Project SHE demonstration study

This article from Implementation Science describes the results of a demonstration project in Philadelphia, PA, USA to integrate PrEP provision into a syringe services programme for women who inject drugs.

Research, Service Delivery

Document
11 August 2023

Feasibility of Long Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.

This poster presentation, delivered at IAS 2023 by the Whitman-Walker Institute, describes the integration of long acting injectable cabotegravir for PrEP, administered by community health workers, or non medically licensed staff, in a primary health clinic in Washington, D.C., USA.

Research, Service Delivery

Document
6 April 2023

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

This journal article from Antimicrobial Agents and Chemo Therapy shares an extended report on HIV infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm).

Monitoring & Evaluation

External Link
27 February 2023

Mobile Phone Apps for HIV Prevention Among College-Aged Black Women in Atlanta: Mixed methods study and user-centered prototype

This article from JMIR Formative Research discusses the process of designing a mobile health app for HIV prevention, including pre-exposure prophylaxis, and sexual and reproductive health incorporating the perspectives of college-aged Black women in Atlanta, Georgia, USA.

Demand Creation/Marketing, Research, Service Delivery

External Link